Live-attenuated respiratory syncytial virus (RSV) vaccines are highly immunogenic among HIV-exposed uninfected (HEU) pediatric patients, according to results of a study published in Open Forum ...

Shingles vaccine industry is projected to witness a CAGR of 10.1% during the period 2025-2034. This growth can be attributed ...

The global Veterinary Vaccines Market, valued at US$8.93 billion in 2023, is forecasted to grow at a robust CAGR of 6.1%, ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

Live attenuated vaccines are antigenic substances composed of a viable (living) pathogen, such as a virus or bacterium. The pathogen is altered so that it is less virulent or avirulent (attenuated).

Oral vaccines encounter several challenges, here research explore developing and testing dmLT and saponin combination ...

Studies conducted in mice have shown that the COVID-19 vaccine being developed by researchers at the University of São ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was ...